Evgen Pharma

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Company Growth (employees)
Type
Public
HQ
Liverpool, GB
Founded
2007
Size (employees)
2 (est)
Website
evgen.com
Evgen Pharma was founded in 2007 and is headquartered in Liverpool, GB

Evgen Pharma Office Locations

Evgen Pharma has offices in Liverpool and London
Liverpool, GB (HQ)
Liverpool Science Park Innovation Centre 2 146 Brownlow Hill
London, GB
107 Cheapside

Evgen Pharma Financials and Metrics

Evgen Pharma Financials

GBP

Net income (FY, 2017)

(3.1 m)

Market capitalization (20-Oct-2017)

13.7 m

Closing share price (20-Oct-2017)

0.2

Cash (31-Mar-2017)

3.9 m
Evgen Pharma's current market capitalization is £13.7 m.
GBPFY, 2015FY, 2016FY, 2017

EBITDA

(1.2 m)

EBIT

(1.2 m)

Pre tax profit

(2.3 m)(3.2 m)(3.6 m)

Income tax expense

30 k85 k576 k
GBPFY, 2015FY, 2016FY, 2017

Cash

163 k7.1 m3.9 m

Accounts Receivable

6 k3 k

Current Assets

310 k7.3 m4.6 m

PP&E

1 k6 k11 k
    GBPFY, 2015FY, 2016FY, 2017

    Net Income

    (2.3 m)(3.1 m)(3.1 m)

    Cash From Operating Activities

    (900 k)(1.6 m)(3.2 m)

    Cash From Financing Activities

    750 k8.6 m

    Net Change in Cash

    (151 k)5 m(1.3 m)
      Y, 2017

      Financial Leverage

      1.1 x
      Show all financial metrics

      Evgen Pharma Market Value History

      Traffic Overview of Evgen Pharma

      Evgen Pharma Online and Social Media Presence

      Evgen Pharma Company Life and Culture

      You may also be interested in